Patients derived benefit for pembrolizumab-combination for OS and PFS across all PD-L1 subgroups, which include a PD-L1 tumour proportion score of <1%, 1–49%, and ≥50%, respectively [22]. This evidence concerns the gene CD274 and neoplasm.